A recent systematic review and meta-analysis evaluated the performance of Uromonitor®, a urine-based biomarker test for non–muscle-invasive bladder cancer (NMIBC). Analyzing 1,190 tests across four studies, Uromonitor® achieved 80.2% sensitivity, 96.9% specificity, and a high negative predictive value (96.6%). Compared to urinary cytology, Uromonitor® significantly improved sensitivity and test accuracy, reducing unnecessary cystoscopies by up to 825 per 1,000 patients. Its DNA-based approach effectively detects key mutations (TERT, FGFR3, KRAS), making it a reliable, non-invasive alternative for NMIBC monitoring. These findings position Uromonitor® as a superior tool for optimizing bladder cancer surveillance.

Read the Full Article